Skip to content

Author

Yong-Xian Zhuang

We have 2 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B073: Rational combination strategies enhance the depth and durability of zoldonrasib antitumor response in preclinical models of KRAS G12D pancreatic cancer

R Rational combination strategies of zoldonrasib with mechanistically distinct agents can enhance antitumor activity relative to the respective monotherapies, and potentially delay emergence of resistance to RAS(ON) inhibition in preclinical models of KRAS G12D PDAC.

Urszula N. Wasko, Yong-Xian Zhuang, Marie Ménard et al. · 0 citations
Aug 2026

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.